ABCSG 32 Summary

Multicentre, randomized phase-II-study of neoadjuvant trastuzumab plus docetaxel with and without bevacizumab and trastuzumab plus non-pegylated liposome-encapsulated doxorubicin (NPLD) with and without bevacizumab

Start: 2011
Coordinating investigator: Steger, G√ľnther; Vienna
Sample size: 100
Design:
(Click to enlarge)
ABCSG-32 Design

Link for studyteam-members only

Further information about this trial

Access to these informations only with keyword. If required, please ask the responsible project manager.